Efficacy and Safety of LCZ696, a First-in-Class Angiotensin Receptor Neprilysin Inhibitor, in Asian Patients With Hypertension

Kario, Kazuomi; Sun, Ningling; Chiang, Fu‐Tien; Supasyndh, Ouppatham; Hong Baek, Sang; Inubushi-Molessa, Akiko; Zhang, Ying; Gotou, Hiromi; Lefkowitz, Martin; Zhang, Jack

doi:10.1161/hypertensionaha.113.02002

Public

Efficacy and Safety of LCZ696, a First-in-Class Angiotensin Receptor Neprilysin Inhibitor, in Asian Patients With Hypertension

Published in Hypertension • Jan 20, 2014

Authors:

Kazuomi Kario

Ningling Sun

Fu‐Tien Chiang

Abstract

LCZ696 (Japanese adopted name: sucabitril valsartan sodium hydrate), a first-in-class angiotensin receptor neprilysin inhibitor, concomitantly inhibits neprilysin and blocks angiotensin type 1 receptor. This randomized, double-blind, placebo-controlled study, the first in Asia for this drug, evaluat...

Subject

Medicine

Placebo

Ambulatory blood pressure

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!